Core Viewpoint - Neurothera Labs Inc. has received a patent from the Israel Patent Office for its proprietary combination of opioids and N-acylethanolamines, aimed at enhancing the therapeutic effects of opioids while reducing side effects [1][2]. Group 1: Patent and Technology - The newly granted patent in Israel complements existing patents in Europe, Japan, Australia, and Canada, thereby strengthening the global intellectual property protection for Neurothera's opioid-based platform [2]. - The patented technology utilizes N-acylethanolamines, such as palmitoylethanolamide (PEA), to enhance opioid analgesia through synergistic mechanisms, allowing for effective pain relief at lower doses [2]. Group 2: Research and Efficacy - A pre-clinical study evaluated the nociceptive effect of PEA combined with opiates like oxycodone, demonstrating that the proprietary drug combination could reduce adverse psychoactive effects associated with oxycodone [3][4]. - The study found that PEA not only mitigated some negative side effects of oxycodone but also prolonged its analgesic effects across all doses tested [4]. Group 3: Market Context - The global market for oxycodone drugs is projected to be valued between $5.5 billion and $5.7 billion in 2024, highlighting the significant sales potential despite the risks associated with opioid use [5]. - The "opioid-sparing" effect of Neurothera's combination may lead to reduced opioid dosages, potentially addressing issues like addiction and respiratory depression [6]. Group 4: Company Perspective - The CEO of Neurothera emphasized the importance of the patent grant, which validates the advantages of their proprietary combination in providing effective pain relief while ensuring patient safety [7].

Sign in to access your portfolio Sign in ...

Core Viewpoint - PharmaCielo Ltd. has successfully revoked the failure to file cease trade order (FFCTO) and is set to resume trading on the TSX Venture Exchange after filing its required financial documents [2][3]. Financial Performance - For the six months ended September 30, 2025, PharmaCielo reported revenue of $1,212,000, a decrease from $2,113,000 in the same period of 2024 [4]. - The company recorded an adjusted EBITDA loss of $531,000, improving from a loss of $2,218,000 year-over-year [4]. - The net loss for the period was $2,687,000, down from $5,219,000 in the previous year, with a net loss per share of $0.014 compared to $0.031 [4]. Corporate Developments - The Ontario Securities Commission has revoked the FFCTO issued on August 5, 2025, allowing the company to move forward with its operations [2]. - The company has strengthened its balance sheet and streamlined operations in Colombia, aligning commercial efforts with the growing demand for high-quality cannabis products [3]. Debt and Financing - PharmaCielo has an aggregate principal balance of $2,150,000 in secured bridge loans from related parties, with an interest rate of 11% per annum [5]. - The company has issued 985 debenture units for total gross proceeds of $985,000, maturing on June 30, 2026, with each unit consisting of an 11% secured debenture and non-transferable common share purchase warrants [8]. Working Capital and Liabilities - As of September 30, 2025, PharmaCielo reported a working capital deficiency of $20,026,086, but has maintained adequate resources to support operations [10]. - Current liabilities include accounts payable and accrued liabilities of $5.73 million, current debt of $2.39 million, and current debentures of $15.43 million [13]. Future Outlook - The company aims to build consistent export volumes, deepen international partnerships, and selectively expand into profitable markets [3].

– Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine development-stage assets held within Takeda’s externalized assets portfolio – EMERYVILLE, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has amended its collaboration, originally established in 2006, with Takeda through a stra ...

Acquisition and Business Strategy - Meta is set to acquire Manus, a Singapore-based AI startup specializing in general-purpose AI agents, to enhance its consumer and business product offerings with advanced AI capabilities [3] - The financial terms of the acquisition have not been disclosed, but Manus has achieved a $125 million annual revenue run rate shortly after launching its subscription-based AI agent services [4] - This acquisition aligns with Meta CEO Mark Zuckerberg's focus on AI infrastructure and monetization strategies beyond metaverse initiatives, marking the company's fifth AI-related acquisition in 2025 [5] Industry Developments - Boeing has secured an $8.6 billion contract from the U.S. Air Force to produce F-15 fighter jets for the Israeli Air Force, with the contract including options for additional aircraft [6] - The contract involves the design, integration, and delivery of 25 new F-15IA aircraft, with work expected to be completed by the end of 2035 [6] - Novo Nordisk has reduced the price of its GLP-1 medication Wegovy in China by nearly 50% for its two highest dosage strengths, in anticipation of increased competition from generics following the expiration of its patent in March 2026 [7][8]

“We expect the minutes to the December meeting to note ongoing disagreement among FOMC participants about the appropriate policy path over the near term,” Goldman Sachs economists wrote in a note this week.Today, market watchers will pay close attention to the publication of the minutes from the Fed’s December 9-10 meeting. The minutes will be scrutinized to assess policymakers’ appetite for additional rate cuts. The FOMC lowered its benchmark rate this month for the third time in a row, though officials’ m ...

These high-octane dividend stocks -- sporting an average yield of 11.25% -- have the catalysts needed to sustainably pad the pocketbooks of income seekers.For more than a century, Wall Street has proven it's a bona fide wealth-creating machine. With thousands of publicly traded companies and exchange-traded funds to choose from, there's a good chance one or more securities can help you reach your financial goals.But not all investment strategies are created equally on Wall Street. According to a comprehensi ...

Core Viewpoint - Newsmax, despite having over 50 million regular viewers in the U.S., faces significant competition and challenges in the market, particularly from larger players like Fox Corp, and is predicted to underperform compared to other stocks in the next five years [1][2]. Group 1: Newsmax Overview - Newsmax has a market capitalization of approximately $1.1 billion and has recently expanded into Europe and the Middle East, which may increase its audience [1][2]. - The company reported a net loss of $4.1 million in the third quarter of 2025, indicating ongoing profitability challenges [7]. Group 2: Competitor Analysis - Fox Corp - Fox Corp, Newsmax's largest competitor, has a market cap of nearly $31 billion, significantly larger than Newsmax's [4]. - In the latest quarter, Fox reported a profit of $690 million, while Newsmax's revenue growth is in low single-digit percentages [7]. - Fox's shares have a price-to-sales ratio of 1.8, which is more attractive compared to Newsmax's forward sales multiple of 6 [7]. Group 3: Competitor Analysis - Mirum Pharmaceuticals - Mirum Pharmaceuticals has a market cap of around $4 billion and reported a revenue increase of 47% year-over-year in the third quarter, driven by its liver disease drug Livmarli [8][9]. - The company is optimistic about its pipeline, including potential blockbuster drugs and plans to acquire Bluejay Therapeutics, which could enhance its portfolio [11][12]. Group 4: Competitor Analysis - The Trade Desk - The Trade Desk, a leading advertising technology company, has a market cap of $19 billion and is expected to outperform Newsmax in the long term [13][15]. - The Trade Desk's growth opportunities are bolstered by the rise of ad-supported connected TV and international market expansion [15].

Core Viewpoint - Novo Nordisk is facing significant challenges, including a sharp decline in stock price and increased competition in the GLP-1 drug market, leading to a major leadership shakeup and investor skepticism about its growth potential [1][18]. Group 1: Company Performance and Market Position - Novo Nordisk's stock has dropped 50% year-to-date, marking its worst performance since listing on Nasdaq Copenhagen over three decades ago, with shares trading around 320 Danish kroner compared to over 1,000 kroner at its peak in mid-2024 [18][19]. - The company is experiencing pressure from competitors like Eli Lilly, which has introduced rival drugs, and from compounding pharmacies producing cheaper versions of semaglutide [19][25]. - Despite the challenges, Goldman Sachs analysts maintain a "Buy" rating on Novo Nordisk, citing potential volume opportunities in the evolving obesity market [26]. Group 2: Drug Development and Potential Benefits - Semaglutide, marketed as Ozempic and Wegovy, is a GLP-1 receptor agonist initially developed for diabetes management but has gained popularity for its weight-loss properties, generating billions in annual revenue for Novo Nordisk [3]. - The U.S. FDA has approved semaglutide for various conditions, including liver disease and reducing cardiovascular risks in overweight individuals [4]. - Emerging research suggests that GLP-1 drugs may have additional benefits, such as reducing cravings for food, alcohol, and drugs by affecting the brain's reward pathways [6][9]. Group 3: Research and Clinical Trials - Observational studies indicate that semaglutide may help manage excessive cravings and could be effective in treating conditions like alcohol use disorder, with clinical trials showing reduced alcohol consumption in patients [10][12]. - A recent clinical trial aimed at assessing semaglutide's impact on Alzheimer's disease did not meet its primary goal, leading to disappointment among investors, but some experts believe the trial provided valuable insights for future research [12][15]. - There is ongoing interest in exploring semaglutide's effects on brain functions and its potential as a preventative therapy for cognitive decline [7][16].

Major U.S. indices closed lower on Monday, with the Dow Jones Industrial Average slipping 0.5% to 48,461.93. The S&P 500 declined 0.35% to 6,905.74, while the Nasdaq fell 0.5% to 23,474.34.These are the top stocks that gained the attention of retail traders and investors throughout the day:Brand Engagement Network Inc. (NASDAQ:BNAI)Brand Engagement Network stock surged by 108.75%, closing at $2.50. It reached an intraday high of $2.91 and a low of $1.77, with a 52-week range between $11.80 and $1.18. In the ...